Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II pilot trial of 'chemo-switch' regimen [vinblastine, cisplatin, interferon alpha, interleukin 2] of biochemotherapy followed by daily low-dose temozolomide plus sorafenib in advanced melanoma

Next Previous
Search
Trial Profile

Phase II pilot trial of 'chemo-switch' regimen [vinblastine, cisplatin, interferon alpha, interleukin 2] of biochemotherapy followed by daily low-dose temozolomide plus sorafenib in advanced melanoma

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sorafenib (Primary) ; Cisplatin; Interferon alpha; Interleukin-2; Temozolomide; Vinblastine
  • Indications Malignant melanoma
  • Focus Therapeutic Use

Most Recent Events

  • 20 Mar 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
  • 31 May 2008 New trial record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top